  Measuring the oligomerization of plasma membrane proteins is rife with
biophysical and biomedical implications. This is particularly true for GPCRs, a
large family of proteins representing the targets of over one third of all FDA
approved medications. Over the last thirty years, fluorescence microscopy has
been the leading approach to address this problem. However, in spite of a large
number of studies and approaches, for most GPCRs the results have remained
highly contentious, possibly due to the large spectrum of specific methods
employed.
